NASDAQ:CMPX Compass Therapeutics (CMPX) Stock Price, News & Analysis $1.63 -0.03 (-1.81%) (As of 09/18/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Compass Therapeutics alerts: Email Address About Compass Therapeutics Stock (NASDAQ:CMPX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Compass Therapeutics alerts:Sign Up Key Stats Today's Range$1.63▼$1.7550-Day Range$0.90▼$1.7152-Week Range$0.77▼$2.34Volume326,156 shsAverage Volume419,438 shsMarket Capitalization$224.27 millionP/E RatioN/ADividend YieldN/APrice Target$7.67Consensus RatingBuy Company OverviewCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Read More… Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Compass Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 57th PercentileCompass Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 521st out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCompass Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCompass Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Compass Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.42) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Therapeutics is -4.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Therapeutics is -4.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompass Therapeutics has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Compass Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.17% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Compass Therapeutics has recently increased by 4.49%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompass Therapeutics does not currently pay a dividend.Dividend GrowthCompass Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.17% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Compass Therapeutics has recently increased by 4.49%, indicating that investor sentiment is decreasing. News and Social Media2.8 / 5News Sentiment1.10 News SentimentCompass Therapeutics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Compass Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for CMPX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Compass Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders30.00% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Compass Therapeutics' insider trading history. Receive CMPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPX Stock News HeadlinesCompass Therapeutics (NASDAQ:CMPX) Stock Rating Upgraded by LADENBURG THALM/SH SHSeptember 18 at 2:09 AM | americanbankingnews.comCompass Therapeutics to Participate in Upcoming Investor EventsSeptember 3, 2024 | globenewswire.comKamala Harris To Tank the Market?URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…September 19, 2024 | Paradigm Press (Ad)Institutional investors own a significant stake of 50% in Compass Therapeutics, Inc. (NASDAQ:CMPX)August 23, 2024 | finance.yahoo.comBuy Rating Affirmed: Compass Therapeutics’ Promising Pipeline and Prudent Financial OutlookAugust 12, 2024 | markets.businessinsider.comCompass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate UpdateAugust 12, 2024 | finance.yahoo.comCompass Therapeutics to Participate in the Wedbush PacGrow Healthcare ConferenceAugust 7, 2024 | globenewswire.comCompass Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 30, 2024 | globenewswire.comSee More Headlines CMPX Stock Analysis - Frequently Asked Questions How have CMPX shares performed this year? Compass Therapeutics' stock was trading at $1.56 at the beginning of 2024. Since then, CMPX stock has increased by 4.5% and is now trading at $1.63. View the best growth stocks for 2024 here. How were Compass Therapeutics' earnings last quarter? Compass Therapeutics, Inc. (NASDAQ:CMPX) released its quarterly earnings data on Monday, August, 12th. The company reported ($0.10) EPS for the quarter, meeting analysts' consensus estimates of ($0.10). The company earned $0.85 million during the quarter. When did Compass Therapeutics IPO? Compass Therapeutics (CMPX) raised $50 million in an initial public offering (IPO) on the week of November 16th 2020. The company issued 9,000,000 shares at $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel served as the underwriters for the IPO and Raymond James was co-manager. Who are Compass Therapeutics' major shareholders? Compass Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.21%), Renaissance Technologies LLC (0.10%), Rhumbline Advisers (0.10%) and Ground Swell Capital LLC (0.09%). Insiders that own company stock include Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib. View institutional ownership trends. How do I buy shares of Compass Therapeutics? Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/12/2024Today9/18/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMPX CUSIPN/A CIK1738021 Webwww.compasstherapeutics.com Phone617-500-8099FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$7.67 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+370.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,490,000.00 Net MarginsN/A Pretax Margin-5,557.88% Return on Equity-30.89% Return on Assets-29.36% Debt Debt-to-Equity RatioN/A Current Ratio16.15 Quick Ratio16.15 Sales & Book Value Annual Sales$850,000.00 Price / Sales263.85 Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book1.39Miscellaneous Outstanding Shares137,589,000Free Float96,312,000Market Cap$224.27 million OptionableNot Optionable Beta0.88 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:CMPX) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinThe Bitcoin Halving ignited the 2024 boom, and altcoins are primed to SKYROCKET. Last year we tipped off ou...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.